| Assessment Status | Rapid Review Complete |
| HTA ID | 23054 |
| Drug | Pitolisant hydrochloride |
| Brand | Wakix® |
| Indication | Pitolisant hydrochloride (Wakix®) is indicated in adults, adolescents, and children aged 6 years and older for the treatment of narcolepsy with or without cataplexy |
| Assessment Process | |
| Rapid review commissioned | 30/08/2023 |
| Rapid review resubmission required | 12/09/2023 |
| Rapid review completed | 04/10/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that pitolisant hydrochloride (Wakix®) for adolescents and children aged 6 years and older not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
